ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Clinical trials for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) trials appear
Sign up with your email to follow new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation to the gut boosts cancer-killing power of immunotherapy in esophageal cancer trial
Disease control Recruiting nowThis study tests whether adding a single, low dose of radiation to the small intestine can make a standard immunotherapy-plus-chemotherapy regimen work better for people with esophageal cancer that cannot be easily removed by surgery. About 43 adults with borderline resectable or…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Chuangzhen Chen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy-Chemo cocktail aims to boost esophageal cancer surgery success
Disease control Recruiting nowThis phase II trial is testing whether combining the immunotherapy drug adebrelimab with two chemotherapy drugs (nab-paclitaxel and carboplatin) before surgery can help patients with borderline resectable esophageal cancer. The goal is to increase the chance of completely removin…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for elderly esophageal cancer patients: immunotherapy without chemo
Disease control Recruiting nowThis study tests a drug called tislelizumab in people aged 70 and older with advanced esophageal cancer who are not healthy enough for standard chemotherapy. The drug is given through an IV and aims to help patients live longer and with better quality of life. Researchers will tr…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: University Hospital, Clermont-Ferrand • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Promising combo aims to wipe out esophageal cancer before surgery
Disease control Recruiting nowThis study tests whether adding adalimumab to standard chemotherapy and radiation before surgery can help eliminate esophageal cancer more effectively. About 37 adults with resectable esophageal squamous cell carcinoma will receive this combination. The main goal is to see how ma…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New 'Smart Bomb' drug targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study is testing a new drug called ALX2004 in people with advanced lung, head and neck, esophageal, or colorectal cancers that have not responded to standard treatments. ALX2004 is an antibody-drug conjugate designed to deliver a cancer-killing payload directly t…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy shows promise for tough esophageal cancer
Disease control Recruiting nowThis study tests whether giving immunotherapy and chemotherapy before radiation works better than the standard chemoradiation for people with advanced esophageal cancer that cannot be removed by surgery. About 92 adults with stage III-IVA esophageal squamous cell carcinoma will b…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Zunyi Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for tough esophageal cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called QLC5508 against standard chemotherapy in people with advanced esophageal cancer that has worsened after prior treatment. About 466 adults will be randomly assigned to receive either QLC5508 or a chemotherapy chosen by their doctor. The main goal…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Radioactive antibody targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1, PHASE2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New cocktail of drugs aims to fight tough esophageal cancer
Disease control Recruiting nowThis study tests a new oral drug called KC1036 combined with standard immunotherapy (toripalimab) and chemotherapy (paclitaxel and cisplatin) as a first treatment for advanced esophageal cancer that has spread or come back. The trial will enroll 60 adults aged 18-75 who have not …
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Beijing Konruns Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Immunotherapy plus chemo may turn inoperable esophageal cancer into surgical candidates
Disease control Recruiting nowThis Phase 2 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemoradiotherapy can shrink advanced esophageal tumors enough to allow surgery. About 45 people with unresectable esophageal squamous cell carcinoma will receive the combination, followe…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Ming-Yu Lien • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
MRI-Guided boost: could a higher radiation dose beat esophageal cancer?
Disease control Recruiting nowThis early-phase trial tests whether giving an extra, higher dose of radiation guided by MRI can improve outcomes for people with a type of esophageal cancer. About 30 participants will receive standard chemoradiotherapy plus two extra radiation boosts. The main goal is to find t…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New combo therapy may let some esophageal cancer patients skip major surgery
Disease control Recruiting nowThis study tests whether giving chemotherapy plus immunotherapy before treatment can shrink esophageal tumors enough to remove them with an endoscope (a thin tube down the throat) instead of major surgery. About 60 adults with early-stage esophageal cancer will receive two or mor…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE1 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug combo aims to fight advanced esophageal cancer
Disease control Recruiting nowThis study tests whether two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy can help people with advanced esophageal cancer that has come back or spread. About 25 adults will receive the treatment for up to 24 months. The goal is to see if the combination sh…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New radiation schedule tested to improve esophageal cancer treatment
Disease control Recruiting nowThis phase 2 trial is testing whether a shorter, more intense course of radiation (hypofractionated) is safer and more effective than the standard longer course for people with advanced esophageal cancer that cannot be surgically removed. All participants first receive two cycles…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New blood test could spot six gut cancers before symptoms start
Diagnosis Recruiting nowThis study is developing a blood test that looks for tiny genetic molecules called miRNAs, which can signal the presence of several gastrointestinal cancers like liver, pancreatic, and colorectal cancer. Researchers will analyze blood samples from 1,000 adults—half with cancer an…
Matched conditions: ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 08:00 UTC